Comparing Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Bicycle Therapeutics (NASDAQ:BCYC)

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 27.2% of Sienna Biopharmaceuticals shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Sienna Biopharmaceuticals and Bicycle Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
Bicycle Therapeutics	$72.86 million	4.49	-$218.96 million	($3.15)	-1.49

Sienna Biopharmaceuticals has higher earnings, but lower revenue than Bicycle Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sienna Biopharmaceuticals and Bicycle Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sienna Biopharmaceuticals	0	0	0	0	0.00
Bicycle Therapeutics	1	3	5	0	2.44

Bicycle Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 198.51%. Given Bicycle Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Sienna Biopharmaceuticals.

Profitability

This table compares Sienna Biopharmaceuticals and Bicycle Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals	N/A	N/A	N/A
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Summary

Bicycle Therapeutics beats Sienna Biopharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.